During that time, he helped put the finishing touches on a $39 billion acquisition, while also parrying concerns over the much-anticipated Covid-19 vaccine AstraZeneca developed with the University of Oxford. That two such important developments should emerge while he was in confinement shows how crucial this moment is for the drugmaker — and for Soriot’s legacy. Not even the chief executive officer of one of Britain’s most valuable companies can escape the pandemic’s grasp. But Soriot didn’t let ...
